Diffuse Large B-cell Lymphoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies), By End-User (Hospitals & Clinics, Ambulatory care Centers, Others), By Region and Competition, 2020-2030F

March 2025 | 183 pages | ID: D89D3A7770E2EN
TechSci Research

Abstracts

Global Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4.02 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 7.91% through 2030. The Global Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market is experiencing significant growth due to rising incidence rates, advancements in targeted therapies, and increasing awareness about early diagnosis. DLBCL, the most common subtype of non-Hodgkin’s lymphoma, has seen a surge in cases, driving demand for effective treatment options. The market is benefiting from the expanding approval of novel therapies, including CAR-T cell treatments, bispecific antibodies, and monoclonal antibodies, which are improving survival rates and offering new hope for patients with relapsed or refractory disease. Pharmaceutical companies and research institutions are actively investing in drug development, leading to a robust pipeline of innovative therapies. The shift toward personalized medicine and biomarker-driven treatment approaches is further revolutionizing the market, enabling tailored therapies that enhance treatment efficacy and reduce adverse effects.

Key Market Drivers

Rising Incidence of Diffuse Large B-cell Lymphoma (DLBCL)

The rising incidence of Diffuse Large B-cell Lymphoma (DLBCL) is a significant driving force behind the growth of the global DLBCL therapeutics market. DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25% to 30% of all NHL cases worldwide. In the United States, the age-standardized incidence rate for DLBCL is 7.2 per 100,000 individuals, with higher rates observed among non-Hispanic whites (9.2 per 100,000). In the United Kingdom, about 5,000 people are diagnosed with DLBCL annually, representing more than 40% of adult NHL cases. This increasing prevalence is a cause for concern and a catalyst for innovative treatment approaches.

Several factors contribute to the escalating incidence of DLBCL. The aging global population is a significant factor, as DLBCL predominantly affects older adults. Most individuals diagnosed with DLBCL are 65 years or older. As life expectancy increases, the number of older individuals at risk for DLBCL rises, thereby expanding the patient population in need of treatment.

Key Market Challenges

High Cost of Innovative Therapies

The high cost of innovative therapies stands as a significant barrier hindering the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, as one of the most common subtypes of non-Hodgkin lymphoma, necessitates cutting-edge treatments to improve patient outcomes. However, the exorbitant prices associated with these therapies create formidable challenges for both patients and healthcare systems.

In recent years, the development of novel treatments, such as Chimeric Antigen Receptor T-cell therapy (CAR-T therapy) and targeted drugs, has provided new hope for DLBCL patients. CAR-T therapy, for instance, involves genetically modifying a patient's T-cells to attack cancer cells specifically. While these therapies offer remarkable results, they often come with a staggering price tag. CAR-T therapies can cost hundreds of thousands of dollars, putting them out of reach for many patients.

Key Market Trends

Immunotherapy Revolution

The immunotherapy revolution is playing a pivotal role in boosting the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, being a prevalent and aggressive subtype of non-Hodgkin lymphoma, has long posed significant challenges for treatment. However, recent breakthroughs in immunotherapy have transformed the landscape of DLBCL therapeutics.

Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are among the key drivers of this revolution. These drugs work by blocking specific proteins that inhibit the immune system's response to cancer cells. In DLBCL, they have shown promising results by reinvigorating the body's immune defenses against cancer. Patients who have exhausted conventional treatment options, especially those with relapsed or refractory DLBCL, have witnessed remarkable responses to these immunotherapies.

Another groundbreaking immunotherapy approach in DLBCL is Chimeric Antigen Receptor T-cell therapy (CAR-T therapy). CAR-T therapies, like axicabtagene ciloleucel and tisagenlecleucel, involve genetically modifying a patient's own T-cells to express chimeric antigen receptors that target specific proteins on the surface of DLBCL cells. This precise targeting has led to high response rates and prolonged remissions in some patients, even those with refractory disease.

Key Market Players

• Gilead Sciences Inc
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• CTI BioPharma Corp.
• Celltrion Healthcare Co. Ltd.
• Bristol Myers Squibb Company
• AbbVie Inc

Report Scope:

In this report, the Global Diffuse Large B-cell Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Class:
• Cisplatin
• Carboplatin
• 5-fluorouracil
• Docetaxel
• Paclitaxel
• Methotrexate
• Other Drugs
• Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Therapy:
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies
• Global Diffuse Large B-cell Lymphoma Therapeutics Market, By End-User:
• Hospitals &Clinics
• Ambulatory care Centers
• Others
• Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diffuse Large B-cell Lymphoma Therapeutics Market.

Available Customizations:

Global Diffuse Large B-cell Lymphoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

4.1. Market Size & Forecast
  4.1.1. By Value
4.2. Market Share & Forecast
  4.2.1. By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs)
  4.2.2. By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies)
  4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  4.2.4. By Region
  4.2.5. By Company (2024)
4.3. Market Map
  4.3.1. By Drug Class
  4.3.2. By Therapy
  4.3.3. By End-User
  4.3.4. By Region

5. ASIA PACIFIC DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Drug Class
  5.2.2. By Therapy
  5.2.3. By End-User
  5.2.4. By Country
5.3. Asia Pacific: Country Analysis
  5.3.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    5.3.1.1. Market Size & Forecast
      5.3.1.1.1. By Value
    5.3.1.2. Market Share & Forecast
      5.3.1.2.1. By Drug Class
      5.3.1.2.2. By Therapy
      5.3.1.2.3. By End-User
  5.3.2. India Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    5.3.2.1. Market Size & Forecast
      5.3.2.1.1. By Value
    5.3.2.2. Market Share & Forecast
      5.3.2.2.1. By Drug Class
      5.3.2.2.2. By Therapy
      5.3.2.2.3. By End-User
  5.3.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    5.3.3.1. Market Size & Forecast
      5.3.3.1.1. By Value
    5.3.3.2. Market Share & Forecast
      5.3.3.2.1. By Drug Class
      5.3.3.2.2. By Therapy
      5.3.3.2.3. By End-User
  5.3.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    5.3.4.1. Market Size & Forecast
      5.3.4.1.1. By Value
    5.3.4.2. Market Share & Forecast
      5.3.4.2.1. By Drug Class
      5.3.4.2.2. By Therapy
      5.3.4.2.3. By End-User
  5.3.5. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    5.3.5.1. Market Size & Forecast
      5.3.5.1.1. By Value
    5.3.5.2. Market Share & Forecast
      5.3.5.2.1. By Drug Class
      5.3.5.2.2. By Therapy
      5.3.5.2.3. By End-User

6. EUROPE DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drug Class
  6.2.2. By Therapy
  6.2.3. By End-User
  6.2.4. By Country
6.3. Europe: Country Analysis
  6.3.1. France Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Drug Class
      6.3.1.2.2. By Therapy
      6.3.1.2.3. By End-User
  6.3.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Drug Class
      6.3.2.2.2. By Therapy
      6.3.2.2.3. By End-User
  6.3.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Drug Class
      6.3.3.2.2. By Therapy
      6.3.3.2.3. By End-User
  6.3.4. Italy Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    6.3.4.1. Market Size & Forecast
      6.3.4.1.1. By Value
    6.3.4.2. Market Share & Forecast
      6.3.4.2.1. By Drug Class
      6.3.4.2.2. By Therapy
      6.3.4.2.3. By End-User
  6.3.5. United Kingdom Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    6.3.5.1. Market Size & Forecast
      6.3.5.1.1. By Value
    6.3.5.2. Market Share & Forecast
      6.3.5.2.1. By Drug Class
      6.3.5.2.2. By Therapy
      6.3.5.2.3. By End-User

7. NORTH AMERICA DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drug Class
  7.2.2. By Therapy
  7.2.3. By End-User
  7.2.4. By Country
7.3. North America: Country Analysis
  7.3.1. United States Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drug Class
      7.3.1.2.2. By Therapy
      7.3.1.2.3. By End-User
  7.3.2. Mexico Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drug Class
      7.3.2.2.2. By Therapy
      7.3.2.2.3. By End-User
  7.3.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drug Class
      7.3.3.2.2. By Therapy
      7.3.3.2.3. By End-User

8. SOUTH AMERICA DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Class
  8.2.2. By Therapy
  8.2.3. By End-User
  8.2.4. By Country
8.3. South America: Country Analysis
  8.3.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drug Class
      8.3.1.2.2. By Therapy
      8.3.1.2.3. By End-User
  8.3.2. Argentina Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drug Class
      8.3.2.2.2. By Therapy
      8.3.2.2.3. By End-User
  8.3.3. Colombia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drug Class
      8.3.3.2.2. By Therapy
      8.3.3.2.3. By End-User

9. MIDDLE EAST AND AFRICA DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Class
  9.2.2. By Therapy
  9.2.3. By End-User
  9.2.4. By Country
9.3. MEA: Country Analysis
  9.3.1. South Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Class
      9.3.1.2.2. By Therapy
      9.3.1.2.3. By End-User
  9.3.2. Saudi Arabia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Class
      9.3.2.2.2. By Therapy
      9.3.2.2.3. By End-User
  9.3.3. UAE Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Class
      9.3.3.2.2. By Therapy
      9.3.3.2.3. By End-User

10. MARKET DYNAMICS

10.1. Drivers
10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA THERAPEUTICS MARKET: SWOT ANALYSIS

13. PORTER’S FIVE FORCES ANALYSIS

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

14.1. Gilead Sciences Inc
  14.1.1. Business Overview
  14.1.2. Company Snapshot
  14.1.3. Products & Services
  14.1.4. Current Capacity Analysis
  14.1.5. Financials (In case of listed)
  14.1.6. Recent Developments
  14.1.7. SWOT Analysis
14.2. Novartis AG
14.3. Pfizer Inc.
14.4. Merck & Co. Inc.
14.5. GlaxoSmithKline plc
14.6. F. Hoffmann-La Roche Ltd.
14.7. CTI BioPharma Corp.
14.8. Celltrion Healthcare Co. Ltd.
14.9. Bristol Myers Squibb Company
14.10. AbbVie Inc

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER